DGAP-Adhoc: QIAGEN N.V.: QIAGEN concludes strategic alternatives review; decides to focus on stand-alone business strategy to drive future value creation
|
DGAP-Ad-hoc: QIAGEN N.V. / Key word(s): Strategic Company Decision/Takeover Ad-hoc Announcement pursuant to Article 17 Market Abuse Regulation QIAGEN concludes strategic alternatives review; decides to focus on stand-alone business strategy to drive future value creation Venlo, The Netherlands, December 24, 2019 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces that it has concluded the previously announced review of potential strategic alternatives, and has determined the execution of its current stand-alone business plan represents the best opportunity to drive future value creation. The Management Board and Supervisory Board of QIAGEN, in accordance with their fiduciary duties and in consultation with their financial and legal advisors, held discussions with interested parties to explore potential strategic alternatives that could provide greater value creation opportunities than QIAGEN's already strong stand-alone growth prospects. This process was announced in mid-November after QIAGEN received several conditional, non-binding indications of interest for a full acquisition. On December 24, 2019, the Management Board and Supervisory Board determined that the alternatives to the stand-alone business plan prospects were not compelling and has terminated all discussions so that the full management focus can be on executing the stand-alone plan QIAGEN N.V. Contacts John Gilardi Phoebe Loh Dr. Thomas Theuringer Robert Reitze
24-Dec-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | QIAGEN N.V. |
| Hulsterweg 82 | |
| 5912 PL Venlo | |
| Netherlands | |
| Phone: | +31 7735566 - 00 |
| Fax: | +31 77 35566-58 |
| E-mail: | [email protected] |
| Internet: | www.qiagen.com |
| ISIN: | NL0012169213 |
| WKN: | A2DKCH |
| Indices: | MDAX, TecDAX |
| Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE, SIX |
| EQS News ID: | 943559 |
| End of Announcement | DGAP News Service |
|
|
943559 24-Dec-2019 CET/CEST
QIAGEN NV Aktie
Mehrere Buy-Einschätzungen für QIAGEN NV ohne eine einzige Sell-Einschätzung.
Ein positives, wenn auch bescheidenes, Potenzial für QIAGEN NV mit einem Kursziel von 47 € im Vergleich zum aktuellen Kurs von 40.47 €.
